Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

28 Octubre, 2024

Enviado por remote_content el Lun, 28/10/2024 - 07:54

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

L.Burden and magnitude of risk in HIV/AIDS in the Colombian health system: A real-world data approach Infectio

Enero 3, 2021

Enfermedades infecciosas

Implication of Antibiotic Use during the COVID-19 Pandemic: The Example of Associated Antimicrobial Resistance in Latin America. Antibiotics (Basel).

Marzo 20, 2021

Enfermedades infecciosas

Associated Factors for Mortality in a COVID-19 Colombian Cohort by Epidemic Wave: Is the Predominance of Mu Variant Relevant? Lancet. 12

Diciembre 12, 2022